Rafael Holdings, Inc. is a biotechnology company. The Company holds interests in clinical and early-stage pharmaceutical companies, including a 100% interest in Cyclo Therapeutics, LLC, a biotechnology company focusing on developing its lead clinical candidate, Trappsol Cyclo, which is being evaluated in clinical trials, including an ongoing Phase III trial for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. It also holds an interest in LipoMedix Pharmaceuticals Ltd., a clinical-stage pharmaceutical company; Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, and an interest in Cornerstone Pharmaceuticals, Inc., a cancer metabolism-based therapeutics company. It holds an interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc.
企業コードRFL
会社名Rafael Holdings Inc
上場日Mar 12, 2018
最高経営責任者「CEO」Jonas (Howard S)
従業員数21
証券種類Ordinary Share
決算期末Mar 12
本社所在地520 Broad Street
都市NEWARK
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United States of America
郵便番号07120
電話番号12126581450
ウェブサイトhttps://rafaelholdings.com
企業コードRFL
上場日Mar 12, 2018
最高経営責任者「CEO」Jonas (Howard S)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし